Inhibition of hypoxia-induced calcium responses in pulmonary arterial smooth muscle by acetazolamide is independent of carbonic anhydrase inhibition.
Hypoxic pulmonary vasoconstriction (HPV) occurs with ascent to high altitude and can contribute to development of high altitude pulmonary edema (HAPE). Vascular smooth muscle contains carbonic anhydrase (CA), and acetazolamide (AZ), a CA inhibitor, blunts HPV and might be useful in the prevention of HAPE. The mechanism by which AZ impairs HPV is uncertain. Originally developed as a diuretic, AZ also has direct effects on systemic vascular smooth muscle, including modulation of pH and membrane potential; however, the effect of AZ on pulmonary arterial smooth muscle cells (PASMCs) is unknown. Since HPV requires Ca2+ influx into PASMCs and can be modulated by pH, we hypothesized that AZ alters hypoxia-induced changes in PASMC intracellular pH (pH(i)) or Ca2+ concentration ([Ca2+](i)). Using fluorescent microscopy, we tested the effect of AZ as well as two other potent CA inhibitors, benzolamide and ethoxzolamide, which exhibit low and high membrane permeability, respectively, on hypoxia-induced responses in PASMCs. Hypoxia caused a significant increase in [Ca2+](i) but no change in pH(i). All three CA inhibitors slightly decreased basal pH(i), but only AZ caused a concentration-dependent decrease in the [Ca2+](i) response to hypoxia. AZ had no effect on the KCl-induced increase in [Ca2+](i) or membrane potential. N-methyl-AZ, a synthesized compound lacking the unsubstituted sulfonamide group required for CA inhibition, had no effect on pH(i) but inhibited hypoxia-induced Ca2+ responses. These results suggest that AZ attenuates HPV by selectively inhibiting hypoxia-induced Ca2+ responses via a mechanism independent of CA inhibition, changes in pH(i), or membrane potential.
Shimoda
Larissa A
LA
Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD 21224, USA. shimodal@welch.jhu.edu
Luke
Trevor
T
Sylvester
J T
JT
Shih
Hui-Wen
HW
Jain
Ahamindra
A
Swenson
Erik R
ER
D000086:Acetazolamide / Q000494:pharmacology*; D001574:Benzolamide / Q000494:pharmacology; D002118:Calcium / Q000502:physiology*; D020013:Calcium Signaling / Q000187:drug effects; D002257:Carbonic Anhydrase Inhibitors / Q000494:pharmacology*; D002256:Carbonic Anhydrases / Q000378:metabolism*; D005016:Ethoxzolamide / Q000494:pharmacology; D006863:Hydrogen-Ion Concentration; D000860:Hypoxia / Q000503:physiopathology*; D008704:Methazolamide / Q000494:pharmacology; D009131:Muscle, Smooth, Vascular / Q000502:physiology*; D011651:Pulmonary Artery / Q000502:physiology*
D002257:Carbonic Anhydrase Inhibitors; D002256:Carbonic Anhydrases; D001574:Benzolamide; D000086:Acetazolamide; D002118:Calcium; D008704:Methazolamide; D005016:Ethoxzolamide